



DELIVERING RNA – BEYOND THE LIVER

Investor and Business Update Call

December 11, 2023


Forward-Looking Statements



This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the success of strategic transactions, including licensing or partnering, with respect to Altamira Therapeutics' legacy assets, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2022, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.


Speaker

- Thomas Meyer, Ph.D.
- CEO & Chairman
- Swiss, 56 years
- Founded Company in 2003
- Funded Company up to first external financing round in 2008
- Previous experiences:
 - 14 years with Disetronic Group (drug delivery) including CEO and BoD member (>20% sales CAGR, \$3B market cap)
 - Consultant, investor and Board member (various industrial companies)



Strategic Repositioning...

... around our RNA Delivery Technology Platform



OligoPhore™ (siRNA) SemaPhore™ (mRNA) Platforms

- Proprietary peptide for efficient delivery of RNA into target cells (nanoparticles)
- Non-hepatic targets, unlike mainstream technology

RNA Market Taking Off

- Rapidly growing number of RNA therapeutics
- Active M&A, licensing environment
- Delivery platforms for partnering with pharma & biotech

Partnering Legacy Assets

- Unlock intrinsic value of inner ear & OTC assets
- Extra, non-dilutive funding potential

Partial Bentrio Spin-Off

Bentrio® in Allergic Rhinitis

- Drug-free, preservative-free formulation, applied as nasal spray
- Four clinical trials demonstrating safety and efficacy in allergic rhinitis
 - Efficacy: close to medicated sprays
 - Tolerability: close to saline sprays
- Commercialized through distributors
- Significant growth expected
 - Nuance Pharma: market approval in Mainland China and South Korea in 2024
 - Pharma Nordic: launch in Norway Q1 2024
- Advanced discussions on North America, Europe and other key markets



First Step in Transition Process

- Sale of 51% of Altamira Medica AG
 - Cash consideration about \$2.3 million
 - Buyer is Swiss private equity investor
 - CYTO retaining 49% of capital
- CYTO also entitled to 25% of
 - future license income
 - Medica's value appreciation in case of a sale
- CYTO's overall share of upside: 62%
- Financial gain \$5.2 million (IFRS)
- Going forward: reduction in Bentrio related expenditures

Further Legacy Programs to be Partnered

AM-125 in Acute Vestibular Syndrome

- Rx product, applied as nasal spray
- Reformulation of oral betahistine
 - Global market \$450M (ex US) – standard of care for vertigo
 - Poor bioavailability
- Invested \$18 million to date
- Proof of concept in Phase 2, ready for Phase 3 trial
- No comparable product in US
- Structured partnering process initiated




Other Inner Ear Legacy Assets

- Other inner ear development programs
- Early and late-stage tinnitus programs
- Late-stage hearing loss program (AM-111)
- Expect to conclude legacy asset partnering process in H1 2024
- Any proceeds go straight to bottom line

Future Core Business: RNA Delivery Technology



Altamira Therapeutics is using a 'picks and shovels' approach – licensing the technology to partners in the biotech & pharma industry for use with their own RNA



Unique, versatile RNA delivery technology platform

- OligoPhore™ and SemaPhore™
- Suitable for different types of RNA molecules

Addressing major challenges in RNA delivery

- IV administration, reaching extrahepatic targets
- Strong endosomal release (10 x compared to lipid nanoparticles)

Extensive proof of concept

- Successfully tested *in vivo* in 17 different disease models, 30+ papers published

Flagship programs in oncology and rheumatoid arthritis

- First IND expected to be filed in early 2025
- Technology platform out-licensing as business model

Financials

Streamlined costs

Strengthened balance sheet

- ✓ Aligning cost structure with strategic pivot to RNA delivery business
 - Clinical trials completed – key cost drivers in past 3 years
 - Reduction in headcount (-25%)
 - Reduction in office space

- ✓ Reduction in spending levels and cash 'burn rate' to be fully realized in 2024
 - Significant change from 2023 and 2022
 - In addition: positive effects from partial Bentrío spin-off

- ✓ Significant improvement in shareholders' equity
 - \$5 million public offering in July 2023 (last pre-funded warrants exercised mid-Nov)
 - Financial gain from partial Bentrío spin-off (\$5.2 million)

- ✓ Early repayment of FiveT convertible loan
 - \$2.8 million loan, 22-month term, 10% p.a.
 - Early repayment primarily through conversion in shares + cash amortizations

- ✓ Now free of financial debt

Nasdaq

Continued listing requirements

- ✓ Minimum equity requirement
 - Strengthened shareholders' equity
 - Regained compliance on Nov 21, 2023

- ✓ Minimum bid price requirement
 - Share price < \$1
 - 180-day period for remediation expiring Dec 26, 2023

- ✓ Reverse split 20 for 1
 - Address minimum bid price requirement
 - Make shares more attractive for institutional investors

- ✓ Expect to be fully compliant before year-end

The logo features a stylized white icon on the left, resembling a hand or a series of horizontal bars that curve into a shape that suggests a DNA double helix or a folded protein structure.

altamira therapeutics

DELIVERING RNA – BEYOND THE LIVER